Executive summary
US Drug Patent 8,431,806 covers a specific co-encapsulated liposomal combination of daunorubicin + cytarabine for parental administration to treat leukemia (ALL/AML), with tight formulation limits: drug co-encapsulation, molar ratio ~1:5 (daunorubicin:cytarabine), liposome mean diameter <250 nm, and a defined phospholipid/cholesterol composition using DSPC:DSPG:cholesterol ~7:2:1. Independent coverage is strongest for the formulation (composition claim 1; narrower variant claim 6 excluding any additional therapeutic agent) and derivative coverage for methods of treatment (claims 2-5 and 7-10). The claim set is structured to enable both composition-to-method linkages (administering the claimed composition) and design-around pressure through changes to (i) co-encapsulation status, (ii) drug ratio, (iii) particle size, or (iv) lipid/cholesterol molar composition.
What does US Patent 8,431,806 claim for liposomal daunorubicin and cytarabine (DSPC:DSPG:cholesterol 7:2:1)?
Core subject matter: a parental liposomal drug product where daunorubicin and cytarabine are co-encapsulated in the same liposome, using a defined lipid bilayer composition and particle size.
Composition claim 1 (independent)
Claim 1 requires all of the following elements:
- Composition for parental administration
- Liposomes with associated daunorubicin and cytarabine
- Co-encapsulation: daunorubicin and cytarabine are co-encapsulated
- Drug molar ratio: daunorubicin:cytarabine about 1:5
- Particle size: liposomes have mean diameter <250 nm
- Lipid composition: liposomes comprise DSPC, DSPG, cholesterol in molar ratio about 7:2:1
This is a classic “closed box” formulation claim: for infringement, an accused product must meet the entire parameter set simultaneously.
Composition claim 6 (independent variant with a “no added agents” limitation)
Claim 6 includes substantially the same formulation constraints as claim 1, plus an additional limitation:
- The composition comprises no therapeutic agents in addition to the daunorubicin and cytarabine
So, claim 6 targets formulations that keep the regimen strictly two-drug only inside the claimed liposomal carrier.
Claim set relationship
- Claim 1 is broader than claim 6 on the “no additional agents” point.
- Claim 6 is narrower but can be leveraged for enforcement against combination regimens or co-administered payloads formulated within the same product.
How narrow are the key formulation parameters in US 8,431,806 (co-encapsulation, 1:5 ratio, <250 nm, DSPC:DSPG:cholesterol 7:2:1)?
Answer: Very narrow on multiple independent dimensions. Any single parameter shift can create a non-infringement path because each feature is conjunctive.
Co-encapsulation requirement: what does it practically exclude?
Claim 1 requires that both daunorubicin and cytarabine are co-encapsulated.
Practical exclusion buckets:
- Separate liposome populations (daunorubicin-loaded liposomes and cytarabine-loaded liposomes administered together) may avoid the “co-encapsulated” limitation if each drug is not inside the same liposome particle.
- Surface-associated drug without encapsulation may avoid co-encapsulation depending on how “encapsulated” is construed.
- External/adjunct loading (e.g., one drug in liposomes and the other free in solution) can avoid the co-encapsulation requirement.
Drug molar ratio limitation: “about 1:5”
The ratio is a central infringement lever. “About” creates some tolerance, but claim construction typically turns on specification context and prosecution history. For landscape mapping, treat the covered band as:
- daunorubicin:cytarabine near 1:5 molar
- Any formulation materially deviating from that ratio is a key design-around.
Particle size: “mean diameter less than 250 nm”
This is another numeric gate. If an accused product’s mean diameter is at or above 250 nm, it can avoid the claim.
In enforcement, the dispute often turns on:
- which measurement method is used (DLS, NTA, electron microscopy)
- sampling and batch variability
- definition of “mean diameter” in the patent record
Lipid molar ratio: DSPC:DSPG:cholesterol about 7:2:1
This lipid composition constraint is highly specific:
- DSPC (zwitterionic phospholipid)
- DSPG (anionic phospholipid)
- cholesterol (membrane stabilizer)
A competitor can design around by changing:
- phospholipid identity (e.g., replacing DSPG with another anionic lipid)
- changing the molar ratios away from ~7:2:1
- changing cholesterol proportion
Because the ratio is part of the claim, the infringement question becomes whether the accused composition stays within the “about” tolerance.
What methods are protected by US 8,431,806 for leukemia treatment (ALL/AML, human and non-human mammal/avian)?
Answer: The methods are triggered by administration of the claimed composition.
Method claims derived from claim 1
- Claim 2: administer an effective amount of the composition of claim 1 to treat leukemia.
- Claim 3: subject is human.
- Claim 4: subject is non-human mammal or avian.
- Claim 5: leukemia is ALL or AML.
This creates layered method coverage:
- broad treatment method (leukemia generally) + subject-type narrowing + disease-type narrowing.
Method claims derived from claim 6
- Claim 7: administer an effective amount of the composition of claim 6 to treat leukemia.
- Claims 8-10: subject is human/non-human mammal/avian; leukemia is ALL or AML.
Functionally, claim 7 is a method version of the “no additional therapeutic agents” composition limitation.
What is the overall claim scope: composition-only vs method-of-use, and what does that mean for licensing or enforcement?
Answer: US 8,431,806 has both composition and method coverage. In practice:
- Formulation makers face primary exposure:
- companies manufacturing or supplying a liposomal product that matches claim 1 or claim 6 parameter sets.
- Prescribers and clinical operators are typically exposed through induced infringement theories if the administered product is the patented composition.
- Licensing leverage is strongest for manufacturers that can’t easily alter:
- lipid ratio
- particle size
- payload loading ratio
- co-encapsulation format
What patent estate strength does US 8,431,806 suggest for liposomal combination chemotherapy?
Answer: The claims are tightly tethered to a discrete formulation product profile, which often yields moderate enforceability advantages in litigation (because “what you make is what infringes”), but also makes the estate sensitive to precise product-characterization evidence.
Key practical implications for assessing strength:
- The claim language is highly specific, so the patent can be powerful against an accused infringing product that is a close match.
- At the same time, the specificity creates clear design-around routes that formulation teams can execute by changing one or more conjunctive parameters.
In a freedom-to-operate lens, the key is whether a competitor’s product is close enough that it meets:
- co-encapsulation
- 1:5 molar payload ratio (within “about”)
- <250 nm mean size
- DSPC:DSPG:cholesterol ~7:2:1
- no added therapeutic agents for claim 6
How can competitors design around US 8,431,806 without touching “daunorubicin” and “cytarabine”?
Answer: The claim structure encourages single-dimension changes to break at least one element.
High-probability design-around approaches:
- Remove co-encapsulation: use separate liposome populations or separate formulations.
- Change payload molar ratio away from ~1:5: e.g., shift loading so daunorubicin:cytarabine is not “about 1:5.”
- Increase mean diameter to ≥250 nm: or broaden the distribution so mean exceeds the threshold.
- Change lipid composition ratio: alter DSPC:DSPG:cholesterol to a non-infringing ratio; substitute lipids; adjust cholesterol proportion.
- For claim 6 specifically: include an additional therapeutic agent (inside the same composition) so the “no therapeutic agents in addition” limitation is not met.
This design-around map is especially actionable during development because it aligns with measurable product attributes.
What additional adjacent claims or patent types might exist around US 8,431,806’s subject matter (practical landscape inference)?
Answer: Even without listing other specific US patents, the claim style indicates an enforcement posture that typically pairs with adjacent IP layers in the portfolio of the same family.
Common companion patent categories likely in the same family or around it (as landscape concepts):
- liposome composition patents (specific lipid mixtures and ratios)
- drug loading / encapsulation methods
- particle size control approaches
- combination dosing regimens (method claims like 2-5 and 7-10)
- process claims tied to manufacturing parameters producing <250 nm particles
These companion categories matter because they can close design-around gaps that only target the final product composition.
What is the patent’s likely regulatory and commercial relevance for FDA leukemia indications?
Answer: The patent’s method claims align with typical leukemia trials:
- ALL and AML
- parental administration
- human/non-human mammal/avian is included for preclinical and comparative testing support in litigation narratives
For regulatory exposure analysis, the key is whether an FDA-approved product uses:
- the same liposomal system and payload pairing
- the same ratio, particle size profile, and lipid molar ratios
Method claims can be implicated through labeled indications and clinical use, but infringement hinges on the physical formulation attributes tied to composition claim elements.
What products or players are most likely at risk under US 8,431,806 (competition framing)?
Answer: Companies developing liposomal daunorubicin + cytarabine combination therapies where both drugs are loaded into the same liposome at approximately 1:5 molar ratio with DSPC/DSPG/cholesterol ~7:2:1 and <250 nm mean diameter.
Risk drivers in competitive landscapes:
- similarity of the carrier lipid chemistry
- similarity of loading methodology and resultant particle size
- whether the marketed product is a single liposomal formulation (vs mixed separate liposomes)
How do claims 1 and 6 differ for product scope and litigation leverage?
Answer: The delta is the additional-agent limitation.
| Feature |
Claim 1 |
Claim 6 |
| Payload |
daunorubicin + cytarabine |
daunorubicin + cytarabine |
| Encapsulation |
co-encapsulated |
co-encapsulated |
| Payload molar ratio |
~1:5 |
~1:5 |
| Liposome size |
mean diameter <250 nm |
not stated separately, but same claim structure implies the same size constraint as claim 1 |
| Lipid molar ratio |
DSPC:DSPG:cholesterol ~7:2:1 |
same |
| Additional therapeutic agents |
not limited |
composition comprises no therapeutic agents in addition |
Enforcement effect:
- Claim 1 can cover two-drug liposomal products even if other components exist so long as “no therapeutic agents” limitation is not required.
- Claim 6 targets strictly two-therapeutic-agent compositions and can be asserted against “payload-extension” strategies.
Key takeaways
- US 8,431,806 is built around a specific liposomal formulation: co-encapsulated daunorubicin + cytarabine with molar ratio ~1:5, mean diameter <250 nm, and lipid composition DSPC:DSPG:cholesterol ~7:2:1.
- The patent pairs composition claims (1, 6) with method-of-use claims for leukemia treatment (ALL/AML) across human and non-human mammal/avian.
- The conjunctive nature of the claim elements creates clear design-around routes: change co-encapsulation format, shift payload ratio, adjust particle size, alter lipid molar ratios, or add additional therapeutic agents (for claim 6).
- The strongest practical enforcement pathway is product-level characterization because infringement depends on measurable formulation attributes.
FAQs
1) Does US 8,431,806 require both drugs to be inside the same liposome?
Yes. Claim 1 and claim 6 require that daunorubicin and cytarabine are co-encapsulated.
2) What happens if the daunorubicin:cytarabine loading ratio is not about 1:5?
The product can fall outside claim scope because the ratio is a required limitation in both composition claims.
3) Can a liposomal product with mean particle diameter ≥250 nm infringe?
No, if the accused product’s mean diameter is not less than 250 nm, it avoids the explicit size limitation.
4) Are methods of treatment covered even without a matching composition manufacturing process?
Method claims hinge on administration of the claimed composition. If the administered product does not meet claim 1 or claim 6 formulation parameters, method infringement is undermined.
5) How does claim 6 change the enforcement position versus claim 1?
Claim 6 adds that the composition contains no therapeutic agents in addition to daunorubicin and cytarabine, tightening scope against multi-payload combinations.
References
- United States Patent 8,431,806 (claims as provided in prompt).
